Free tool
FAERS Monitor: Cytomel
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 010379 or its brand name (Cytomel, Liothyronine Sodium). Reports on generic versions are filed under their own applications.
Reports
8,771
Serious
3,983
45% of reports
Hospitalization
1,511
Death reported
208
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- drug ineffective969
- headache887
- fatigue860
- nausea587
- dyspnoea562
- pain491
- hypertension471
- malaise451
- weight increased443
- hypothyroidism433
- feeling abnormal420
- dizziness402
- diarrhoea390
- off label use377
- insomnia361
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 79 |
| 2005 | 91 |
| 2006 | 79 |
| 2007 | 129 |
| 2008 | 170 |
| 2009 | 153 |
| 2010 | 269 |
| 2011 | 229 |
| 2012 | 294 |
| 2013 | 314 |
| 2014 | 314 |
| 2015 | 515 |
| 2016 | 727 |
| 2017 | 472 |
| 2018 | 558 |
| 2019 | 560 |
| 2020 | 640 |
| 2021 | 505 |
| 2022 | 946 |
| 2023 | 510 |
| 2024 | 443 |
| 2025 | 427 |
| 2026 | 347 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,045,388 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| hypothyroidismSignal | 433 | 33.0 | 30.0 | 13,222 |
| hypertensionSignal | 471 | 5.3 | 4.9 | 1,671 |
| weight increasedSignal | 443 | 4.8 | 4.3 | 1,320 |
| feeling abnormalSignal | 420 | 4.2 | 3.8 | 1,034 |
| headacheSignal | 887 | 3.4 | 3.2 | 1,541 |
| insomniaSignal | 361 | 3.3 | 2.9 | 568 |
| fatigueSignal | 860 | 2.7 | 2.5 | 915 |
| malaiseSignal | 451 | 2.5 | 2.3 | 400 |
| dyspnoeaSignal | 562 | 2.4 | 2.2 | 461 |
| dizziness | 402 | 1.9 | 1.8 | 184 |
| pain | 491 | 1.9 | 1.8 | 221 |
| nausea | 587 | 1.8 | 1.6 | 207 |
| drug ineffective | 969 | 1.8 | 1.7 | 341 |
| diarrhoea | 390 | 1.4 | 1.3 | 56 |
| off label use | 377 | 1.0 | 0.9 | 0 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.